MedTrace Logo

Penicillin Allergy Testing and Resensitization Rate

NCT03942731 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 83

Last updated 2019-07-31

No results posted yet for this study

Summary

Penicillin is one of the earliest discovered antibiotics and a drug of choice for several infections. Up to 10 to 20% of all patients in clinical trial are labeled as penicillin allergic. Most of these patients do not have a true allergy but few have had it verified. Approximately 80% of patients with IgE-mediated penicillin allergy lose their sensitivity after 10 years. Several studies have been conducted denying the risk of sensitization following negative testing of penicillin allergy. Investigators have not had the same experience and have therefore decided to conduct a retrospective study review of 83 adult outpatients with a distant penicillin allergy label and evaluate outcomes of skin retesting six weeks following Drug Provocation Test and challenge.

Conditions

  • Penicillin Allergy

Interventions

OTHER

Behavioral allergy testing protocol

skin tests followed by drug provocation test and skin retesting between 6 weeks and 6 months

Sponsors & Collaborators

  • Centre Hospitalier Régional Metz-Thionville

    lead OTHER

Principal Investigators

  • Sebastien Lefevre, MD · CHR Metz Thionville

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-01
Primary Completion
2019-03-15
Completion
2019-03-15

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03942731 on ClinicalTrials.gov